Table S2 from SDP-LIV1, a Novel and Optimized LIV-1 Antibody–Drug Conjugate Demonstrating Superior Antitumor Efficacy and a Favorable Safety Profile for the Treatment of Solid Tumors
Abstract
Table S2 showes the anti-tumor effect of SDP-LIV1 with different DAR values in MCF-7 xenograft model.
Fields of Study & Subjects
Monoclonal and Polyclonal Antibodies Research
Protein Degradation and Inhibitors
Radiopharmaceutical Chemistry and Applications
Publication details
- Publication date
- 4 February 2026